Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stephen Barker
JEF
Stephen Barker
Jefferies
Wall Street Analyst
Not yet ranked — too few measurable calls.
—
Success Rate
—
Average Return
— vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.

Rating Distribution

23 Buy 12 Hold 0 Sell
Stephen's Stock Coverage 23 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
JP:4151
Kyowa Kirin Co
 Jun 15, 2026 BUY Sell
-15.3% avg upside
4 analysts
$2800.00
10.25% Upside
 ·
JP:4528
ONO Pharmaceutical Co
 May 29, 2026 HOLD Sell
-15.5% avg upside
2 analysts
$2500.00
11.14% Upside
 ·
JP:7747
Asahi Intecc Co
 May 29, 2026 BUY Strong Buy
+0.1% avg upside
2 analysts
$4500.00
28.86% Upside
 ·
JP:4523
Eisai Co
 May 28, 2026 HOLD Buy
+22.4% avg upside
5 analysts
$4000.00
2.55% Upside
 ·
JP:7733
Olympus
 May 18, 2026 BUY Strong Buy
+59.6% avg upside
4 analysts
$2300.00
39.66% Upside
 ·
JP:4519
Chugai Pharmaceutical Co
 May 12, 2026 HOLD Strong Buy
+22.2% avg upside
5 analysts
$8500.00
12.49% Upside
 ·
JP:4568
Daiichi Sankyo Company
 May 06, 2026 BUY Strong Buy
+71.3% avg upside
6 analysts
$3100.00
21.98% Upside
 ·
JP:8086
Nipro
 Apr 30, 2026 HOLD Hold
-8.9% avg upside
1 analyst
$1500.00
8.91% Downside
 ·
JP:4578
Otsuka Holdings Co
 Apr 26, 2026 BUY Strong Buy
+10.1% avg upside
5 analysts
$12500.00
18.84% Upside
 ·
JP:2160
GNI Group
 Apr 03, 2026 BUY Strong Buy
+50.4% avg upside
1 analyst
$3800.00
50.43% Upside
 ·
JP:4503
Astellas Pharma
 Mar 24, 2026 BUY Buy
-2.1% avg upside
5 analysts
$2800.00
30.53% Upside
 ·
JP:6869
Sysmex
 Mar 16, 2026 HOLD Buy
+28.3% avg upside
2 analysts
$1500.00
10.05% Upside
 ·
JP:4506
Sumitomo Dainippon Pharma Co
 Dec 15, 2025 BUY Strong Buy
+34.5% avg upside
3 analysts
$2700.00
83.65% Upside
 ·
JP:4536
Santen Pharmaceutical Co
 Aug 08, 2025 HOLD Buy
+14.7% avg upside
2 analysts
$1700.00
9.37% Downside
 ·
JP:4507
Shionogi & Co
 Oct 25, 2024 HOLD Buy
-2.5% avg upside
5 analysts
$2500.00
10.10% Downside
 ·
JP:4516
Nippon Shinyaku Co., Ltd.
 Oct 21, 2024 HOLD Hold
-6.8% avg upside
3 analysts
$4100.00
3.16% Upside
 ·
JP:4552
JCR Pharmaceuticals Co., Ltd.
 Sep 11, 2024 HOLD Hold
+44.5% avg upside
1 analyst
$660.00
44.49% Upside
 ·
JP:4593
Healios KK
 Sep 09, 2024 BUY Strong Buy
+190.7% avg upside
3 analysts
$320.00
23.97% Upside
 ·
JP:4543
Terumo
 Sep 02, 2024 BUY Strong Buy
+68.2% avg upside
4 analysts
$3500.00
57.35% Upside
 ·
JP:4502
Takeda Pharmaceutical Co
 Aug 13, 2024 BUY Strong Buy
+6.8% avg upside
8 analysts
$5000.00
1.40% Upside
 ·
JP:4587
Peptidream
 Aug 01, 2024 HOLD Buy
+185.2% avg upside
2 analysts
$2700.00
181.23% Upside
 ·
JP:4547
Kissei Pharmaceutical Co
 Jul 30, 2024 HOLD Hold
-8.7% avg upside
1 analyst
$3600.00
8.66% Downside
 ·
JP:4902
Konica Minolta
 Feb 01, 2019 BUY Strong Buy
+29.2% avg upside
3 analysts
 — ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stephen Barker — Frequently Asked Questions
How accurate are Stephen Barker's stock ratings?
Based on the calls 13Foresight could measure, about —% of Stephen's ratings were profitable over a one-year hold, with an average return of —% per rating. We score every analyst the same way, from historical prices.
How is Stephen ranked on 13Foresight?
Stephen Barker is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stephen cover?
Stephen most recently has ratings on JP:4151, JP:4528, JP:7747, JP:4523, JP:7733, JP:4519, JP:4568, JP:8086, JP:4578, JP:2160, JP:4503, JP:6869 and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.